Ash 2025 Embargoed. Mendus to present multiple abstracts at ash 2025, including survival update of advance ii trial with lead program vididencel in aml. August 2025 standing up to prior authorization tired of waiting on insurance companies to approve or deny a request, physicians and lawmakers are joining.
The information contained in all abstracts selected for plenary, oral, and poster presentations at the 2025 ash annual meeting is embargoed until abstracts are posted online. Abstracts for the 2025 ash annual meeting and exposition are now available.